For the Inventor, By the Inventor

Enter assignee name

Raqualia Pharma Inc.

USPTO Granted Patents = 44

CIPO Patents = 13

EPO Patents = 29

Trademarks = 5

Forward Citations = 122

Loading Chart...

Loading Chart...

69 inventors (with patents filed for the assignee):

Mikio Morita (13 out of 17 patents)

Tatsuya Yamagishi (13 out of 18 patents)

Yoshimasa Arano (11 out of 11 patents)

4. Kiyoshi Kawamura (10 out of 22 patents)

5. Kaoru Shimada (8 out of 13 patents)

6. Nobuyuki Takahashi (7 out of 8 patents)

7. Hirohide Noguchi (7 out of 14 patents)

8. Shinichi Koizumi (6 out of 14 patents)

9. Masashi Ohmi (6 out of 6 patents)

10. Masaki Sudo (6 out of 7 patents)

11. Tadashi Inoue (6 out of 13 patents)

12. Kazuo Ando (6 out of 19 patents)

13. Yuji Shishido (6 out of 18 patents)

14. Yasuhiro Iwata (5 out of 13 patents)

15. Ryuichi Yamaguchi (4 out of 4 patents)

Core Competencies:

CRHR2 Antagonist

P2X7 Receptor Antagonist

Nav1.7 Blockers

TTX-S Blockers

Ghrelin Receptor Agonist

5-HT4 Receptor Agonist

Calcium Channel Blockers

Sodium Channel Blockers

TRPM8 Antagonists

Acid Pump Inhibitors

Heterocyclic Derivatives

Pharmaceutical Composition

44 patents: Sort by Forward Citations

1. 12421191 - 3-hydroxyoxindole derivatives as CRHR2 antagonist (2025-09-23),

2. 12295947 - Tetrahydroquinoline derivatives as P2X7 receptor antagonists (2025-05-13),

3. 12110287 - Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers (2024-10-08),

4. 11802120 - Fused cyclic urea derivatives as CRHR2 antagonist (2023-10-31),

5. 11439633 - Tetrahydroquinoline derivatives as P2X7 receptor antagonists (2022-09-13),

6. 11154544 - Amide derivatives as Nav1.7 and Nav1.8 blockers (2021-10-26),

7. 11135270 - Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (CRHR2) (2021-10-05),

8. 11077100 - Tetrahydroquinoline derivatives as P2X7 receptor antagonists (2021-08-03),

9. 11020381 - Biaryloxy derivatives as TTX-S blockers (2021-06-01),

10. 10975070 - Ghrelin receptor agonist for treatment of cachexia (2021-04-13),

11. 10512635 - Uses of benzimidazole derivative for nocturnal acid breakthrough (2019-12-24),

12. 10179779 - Polymorph forms (2019-01-15),

13. 10137113 - 5-HT4 receptor agonist as a prokinetic agent (2018-11-27),

14. 10093678 - Azaspiro derivatives as TRPM8 antagonists (2018-10-09),

15. 9988370 - Benzisoxazole derivative salt (2018-06-05),

RaQualia Pharma Inc. is a leading pharmaceutical company that specializes in the research, development, and commercialization of innovative drugs. With a strong commitment to improving global healthcare, RaQualia Pharma strives to bring new solutions to patients and healthcare professionals. Their expertise lies in various therapeutic areas, including central nervous system disorders, oncology, and immune-related diseases. Through cutting-edge technologies and collaborations with academia and industry partners, RaQualia Pharma aims to contribute to a healthier and brighter future.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

44 Patents

#24 in Aichi

#1,827 in Japan

#15,297 in the World

Raqualia Pharma Inc.

Forward Citations = 122

69 inventors:

Mikio Morita (13 out of 17 patents)

Tatsuya Yamagishi (13 out of 18 patents)

Yoshimasa Arano (11 out of 11 patents)

4. Kiyoshi Kawamura (10 out of 22 patents)

5. Kaoru Shimada (8 out of 13 patents)

Please report any incorrect information to support@idiyas.com

Loading…